Shares of Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC – Get Rating) have been assigned an average recommendation of "Hold" from the six brokerages that are currently covering the firm, Marketbeat reports. Five research analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $8.10.
Several research firms recently weighed in on TRHC. StockNews.com upgraded Tabula Rasa HealthCare from a "sell" rating to a "hold" rating in a research report on Thursday, October 20th. Piper Sandler lowered their price objective on Tabula Rasa HealthCare from $6.00 to $4.00 and set a "neutral" rating on the stock in a research report on Monday, November 7th.
Get Tabula Rasa HealthCare alerts:Insider Buying and Selling
In other news, CFO Thomas Cancro bought 11,500 shares of the firm's stock in a transaction that occurred on Monday, December 12th. The shares were bought at an average cost of $4.34 per share, for a total transaction of $49,910.00. Following the completion of the transaction, the chief financial officer now owns 211,500 shares of the company's stock, valued at $917,910. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Michael J. Purcell sold 10,000 shares of the business's stock in a transaction dated Friday, December 9th. The stock was sold at an average price of $4.26, for a total value of $42,600.00. Following the sale, the director now directly owns 88,514 shares in the company, valued at $377,069.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Thomas Cancro bought 11,500 shares of the firm's stock in a transaction that occurred on Monday, December 12th. The stock was purchased at an average price of $4.34 per share, for a total transaction of $49,910.00. Following the completion of the transaction, the chief financial officer now directly owns 211,500 shares of the company's stock, valued at approximately $917,910. The disclosure for this purchase can be found here. 7.25% of the stock is owned by company insiders.
Institutional Investors Weigh In On Tabula Rasa HealthCare
Large investors have recently added to or reduced their stakes in the stock. Teachers Retirement System of The State of Kentucky bought a new stake in Tabula Rasa HealthCare during the third quarter worth approximately $25,000. Delphia USA Inc. increased its stake in Tabula Rasa HealthCare by 27.5% during the second quarter. Delphia USA Inc. now owns 13,851 shares of the company's stock worth $36,000 after acquiring an additional 2,984 shares during the last quarter. SG Americas Securities LLC bought a new stake in Tabula Rasa HealthCare during the second quarter worth approximately $44,000. Creative Planning bought a new stake in Tabula Rasa HealthCare during the second quarter worth approximately $47,000. Finally, Eagle Asset Management Inc. increased its stake in Tabula Rasa HealthCare by 27.8% during the second quarter. Eagle Asset Management Inc. now owns 20,402 shares of the company's stock worth $52,000 after acquiring an additional 4,434 shares during the last quarter. 60.90% of the stock is owned by institutional investors.Tabula Rasa HealthCare Stock Performance
NASDAQ TRHC opened at $6.33 on Wednesday. The company has a market capitalization of $171.69 million, a PE ratio of -1.09 and a beta of 1.58. The business's fifty day moving average is $4.60 and its 200 day moving average is $4.38. Tabula Rasa HealthCare has a fifty-two week low of $2.09 and a fifty-two week high of $13.07.
Tabula Rasa HealthCare (NASDAQ:TRHC – Get Rating) last released its earnings results on Thursday, November 3rd. The company reported ($0.94) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.78). The company had revenue of $77.10 million for the quarter, compared to analysts' expectations of $73.68 million. Tabula Rasa HealthCare had a negative net margin of 46.03% and a negative return on equity of 472.90%. On average, sell-side analysts forecast that Tabula Rasa HealthCare will post -2.11 EPS for the current year.
Tabula Rasa HealthCare Company Profile
(Get Rating)
Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. The company operates in two segments, CareVention HealthCare and MedWise HealthCare. It offers EireneRx, a cloud-based medication decision-support and e-prescribing platform to access patient medication-related information; and MedWise medication therapy management software, a cloud-based platform designed to aid in the identification and resolution of medication and health-related problems.
Recommended Stories
- Get a free copy of the StockNews.com research report on Tabula Rasa HealthCare (TRHC)
- When Will Crane Holdings Take Flight?
- Is It Time To Get Aggressive With Defense Stocks?
- 3 Retail Stocks Ringing the Register in 2023
- Qualcomm Gets a Boost from Analysts, but is it Time to Buy?
- EVgo Stock is Charged Up to Ride the EV Adoption Wave
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.